Oncolix, Inc. (OTCPK:ONCX) seeks acquisitions. The company intends to use the net proceeds received from the issuance of convertible notes to pay the expenses in connection with finishing the company’s phase 1 clinical trials and, up to $0.2 million for marketing and investor relation services, with the balance to be utilized for working capital and for the fees and expenses of introducing new investors into the offering. In the event the company raises at least $2.0 million, it shall be entitled to utilize the proceeds to make an acquisition so long as such acquisition is satisfactory to the majority holders.